Association between vascular endothelial growth factor gene polymorphisms and bladder cancer risk

Yang, Yanfeng; Zhang, Xuepei; Song, Dae‐Kyu; Wei, Jinxin

doi:10.3892/mco.2014.296

Cited by 17 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certain polymorphisms have been identified in the VEGF gene. In order to evaluate the association between the VEGF polymorphism with the various types of cancer risk, numerous molecular epidemiological studies have been performed in different populations recently (6). However, there were no clear conclusions due to inconsistent statistical results.…”

Section: Introductionmentioning

confidence: 99%

Association of the vascular endothelial growth factor -2578C/A polymorphism with cancer risk: A meta-analysis update

et al. 2014

View full text Add to dashboard Cite

The vascular endothelial growth factor (VEGF) -2578C/A polymorphism has been previously reported to be associated with cancer risk; however, the results have been controversial. Therefore, the aim of the present study was to explore the association between the VEGF -2578C/A polymorphism with the cancer risk. A total of 37 case-control studies were identified. The pooled analysis showed that there was no association between VEGF -2578C/A and the risk of cancer, and the odds ratios (ORs) [with the corresponding 95% confidence intervals (95% CIs)] were 0.97 (0.91-1.04) for C vs. A, 0.94 (0.86-1.02) for CC vs. AA, 0.92 (0.80-1.06) for CA vs. AA, 0.96 (0.89-1.03) for CC/CA vs. AA and 0.97 (0.88-1.08) for CC vs. CA/AA. Subgroup analyses according to ethnicity, source of control and type of cancer showed that the VEGF -2578C/A polymorphism is associated with colorectal and lung cancers. Additionally, the polymorphism may decrease the risk of cancer in the Asian population. This VEGF polymorphism was not associated with a risk of cancer for the Caucasian [0.92 (0.76-1.11) for CC vs. AA] and African populations [1.31 (0.67-2.58) for CC vs. AA], and it was not associated with bladder [1.06 (0.74-1.53) for CC/AA] and breast cancers [1.01 (0.90-1.15) for CC/AA]. Therefore, the present meta-analysis indicates that VEGF -2578C/A may only be associated with the risk of colorectal cancer, lung cancer and the Asian population. More studies with larger sample sizes are required to provide more conclusive evidence.

show abstract

Section: Introductionmentioning

confidence: 99%

Association of the vascular endothelial growth factor -2578C/A polymorphism with cancer risk: A meta-analysis update

et al. 2014

View full text Add to dashboard Cite

show abstract

“…There are over 30 variants in VEGF; three of the common polymorphisms in the VEGF gene can influence gene expression and alter the function of the protein, including -634G/C, +936C/T, and +1612G/A (Watson et al, 2000;Ruggiero et al, 2011). VEGF -634G/C, +936C/T, and +1612G/A are reported to have a role in VEGF protein synthesis and in the development of several kinds of cancers Dong-Ju et al, 2014;Lau et al, 2014;Rahoui et al, 2014;Yang et al, 2014b;Yu et al, 2014). Only one previous study has reported an association between VEGF polymorphisms and the development of osteosarcoma .…”

Section: Introductionmentioning

confidence: 99%

Investigation of the role of VEGF gene polymorphisms in the risk of osteosarcoma

Zhang¹,

Bai²,

Zhang³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We conducted a case-control study in a Chinese population, and assessed whether the VEGF -634G/C, +936C/T, and +1612G/A polymorphisms could affect the risk of osteosarcoma and its association with environmental factors. A total of 180 consecutive osteosarcoma patients and 360 controls were included in our study. The genotypes of VEGF -634G/C, +936C/T, and +1612G/A were determined by the polymerase chain reaction-restriction fragment length polymorphism assay. Conditional logistic regression analyses showed that subjects carrying the GG genotype and the G allele of VEGF -634G/C were significantly associated with increased risk of osteosarcoma compared to those with the CC genotype; the ORs (95%CIs) were 2.28 (1.31-3.96) and 1.51 (1.16-1.97) for the GG genotype and G allele, respectively. We found that the GG genotype of VEGF -634G/C was associated with a significantly increased risk 8284 G. Zhang et al. ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (3): 8283-8289 (2015) of osteosarcoma in patients of either gender with younger age and a family history of cancer. In summary, this study found that the VEGF -634G/C gene polymorphism was associated with an increased risk of osteosarcoma.

show abstract

“…Accordingly, these polymorphisms may affect VEGF protein concentrations influencing the angiogenesis process and may be related to inter individual variations in tumor risk, progression, and prognosis. In recent years, the VEGF SNPs have been reported to be associated with cancers of the lung [20], colorectum [21], breast, and bladder [22–23]. Moreover, the VEGF SNPs have also been reported to be associated with clinical outcome of esophageal cancer, renal cell carcinoma and non-small cell lung cancer [24–26].…”

Section: Introductionmentioning

confidence: 99%

Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population

et al. 2017

View full text Add to dashboard Cite

Vascular endothelial growth factor A (VEGFA) is an important angiogenesis regulator, which plays an important role in angiogenesis and progression of tumor, including hepatocellular carcinoma (HCC). We aimed at determining whether single nucleotide polymorphisms of VEGFA gene influence the development and clinical outcomes of HCC. We analyzed four potential functional polymorphisms (936C/T, 634G/C, 1612G/A, 2578C/A) of VEGFA gene in 476 HCC patients and 526 controls using matrix-assisted laser desorption ionization time-of-flight mass spectrometry method. Serum VEGF levels were measured by enzyme-linked immunosorbent assay. The Kaplan-Meier methods with log-rank test and Cox regression models were used to compare survival of resected HCC patients according to the genotype. We found that only the VEGFA 2578C/A polymorphism was significantly associated with decreased risk of HCC (AA/AC vs. CC; adjusted OR = 0.69, 95% CI = 0.51−0.93). Furthermore, the 2578C/A polymorphism was associated with significantly decreased postoperative recurrence (AA/AC vs. CC, adjusted OR = 0.51; 95% CI, 0.29−0.88) and improved overall survival (AA/AC vs. CC, adjusted HR = 0.27, 95% CI = 0.13−0.52) of resected HCC patients. In addition, the VEGF serum levels in HCC patients were significantly higher than those in healthy controls, although no significant association between VEGFA genotype and serum levels of VEGF was observed. These results suggest that the VEGFA 2578 C/A polymorphism may play a potential role in the development and clinical outcome of HCC among Chinese Han population.

show abstract

Association between vascular endothelial growth factor gene polymorphisms and bladder cancer risk

Cited by 17 publications

References 27 publications

Association of the vascular endothelial growth factor -2578C/A polymorphism with cancer risk: A meta-analysis update

Association of the vascular endothelial growth factor -2578C/A polymorphism with cancer risk: A meta-analysis update

Investigation of the role of VEGF gene polymorphisms in the risk of osteosarcoma

Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population

Contact Info

Product

Resources

About